India, Nov. 5 -- Scinai Immunotherapeutics Ltd. (SCNI), a biopharmaceutical company operating a contract development and manufacturing organization (CDMO), on Thursday reported a 167% increase in revenue for the first nine months of 2026, reflecting the expansion of its CDMO operations following the acquisition of Recipharm Israel in February.
Nine-Month Financial Highlights:
Revenue for the nine months ended September 30, 2026, increased to $2.80 million from $1.05 million in the prior-year period.
Gross loss widened to $2.97 million from $1.91 million, while operating loss increased to $6.56 million from $5.64 million.
Net loss narrowed significantly to $0.39 million from $6.24 million a year earlier, primarily reflecting a $6.40 mill...